Literature DB >> 7378253

The pharmacokinetics of metoclopramide in man with observations in the dog.

D N Bateman, C Kahn, D S Davies.   

Abstract

1 The pharmacokinetics of metoclopramide have been studied in eight normal male volunteers. 2 The mean plasma beta half-life was 156.7 min after i.v. administration of 10 mg metoclopramide. 3 After oral dosing of 10 mg the mean half-life was 196.6 min and after 20 mg 317.5 min (P less than 0.05). 4 Bioavailability of a 10 mg oral dose of metoclopramide varied between 32 and 97%. 5 A major urinary metabolite was metoclopramide-N-4-sulphate and the amounts of conjugates appearing in urine to 24 h correlated significantly with the bioavailability. 6 In the dog the metabolic fate of metoclopramide is different to man with conjugation being a minor metabolic pathway. The half-life in the dog does not appear to be dose dependent. 7 The wide differences in bioavailability of metoclopramide in man may contribute to the unpredictable occurrence of side effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378253      PMCID: PMC1429975          DOI: 10.1111/j.1365-2125.1980.tb01064.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Potential source of error in absorption rate calculations.

Authors:  H G Boxenbaum; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1975-08

2.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

3.  Metoclopramide--side effects and safety.

Authors:  O P Robinson
Journal:  Postgrad Med J       Date:  1973-07       Impact factor: 2.401

4.  Gastrointestinal actions of metoclopramide. An experimental study.

Authors:  H I Jacoby; D A Brodie
Journal:  Gastroenterology       Date:  1967-04       Impact factor: 22.682

5.  Dystonic reactions in children caused by metoclopramide.

Authors:  M Casteels-Van Daele; J Jaeken; P Van der Schueren; P Van den Bon
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

6.  Metabolism of isoprenaline in the intestine.

Authors:  C F George; E W Blackwell; D S Davies
Journal:  J Pharm Pharmacol       Date:  1974-04       Impact factor: 3.765

7.  Inhibition by apomorphine of the metoclopramide-induced catalepsy and increase in striatal homovanillic acid content.

Authors:  L Ahtee
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

8.  Metabolism of isoprenaline in dog and man.

Authors:  M E Conolly; D S Davies; C T Dollery; C D Morgan; J W Paterson; M Sandler
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

9.  Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.

Authors:  A Dolphin; P Jenner; C D Marsden; C Pycock; D Tarsy
Journal:  Psychopharmacologia       Date:  1975

10.  Transformation and excretion of drugs in biological systems. 3. Separatory determination of metoclopramide and its N4-glucuronide and N4-sulfonate in rabbit urine and bile.

Authors:  T Arita; R Hori; K Ito; K Ichikawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1970-08       Impact factor: 1.645

View more
  29 in total

Review 1.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Bioavailability of intranasal metoclopramide.

Authors:  M J Ward; D C Buss; J Ellershaw; A Nash; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

5.  Oral bioavailability of high-dose metoclopramide.

Authors:  W B Taylor; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens.

Authors:  H Havsteen; H Nielsen; M Kjaer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Metoclopramide in the reduction of nausea and vomiting associated with combined chemotherapy.

Authors:  R Cox; C E Newman; M J Leyland
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.

Authors:  Mark G Papich; Marilyn N Martinez
Journal:  AAPS J       Date:  2015-04-29       Impact factor: 4.009

9.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

10.  Identification of metoclopramide metabolites in the urine of cattle by gas chromatography-mass spectrometry and high-performance liquid chromatography-photodiode array detection.

Authors:  R D Jones; C D Blanton; J M Bowen
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.